News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
30,613 Results
Type
Article (3915)
Company Profile (3)
Press Release (26695)
Multimedia
Podcasts (26)
Webinars (2)
Section
Business (9853)
Career Advice (85)
Deals (1332)
Drug Delivery (20)
Drug Development (5135)
Employer Resources (10)
FDA (896)
Job Trends (814)
News (16660)
Policy (1364)
Tag
Academia (99)
Accelerated approval (8)
ADA (8)
Adcomms (1)
Allergies (8)
Alliances (2713)
ALS (1)
Alzheimer's disease (133)
Antibody-drug conjugate (ADC) (43)
Approvals (913)
Artificial intelligence (51)
ASCO (24)
Autoimmune disease (21)
Automation (5)
Bankruptcy (6)
Best Places to Work (570)
BIO (1)
BIOSECURE Act (1)
Biosimilars (33)
Biotechnology (3)
Bladder cancer (9)
Brain cancer (6)
Breast cancer (69)
Cancer (437)
Cardiovascular disease (24)
Career advice (79)
Career pathing (2)
CAR-T (6)
CDC (2)
Cell therapy (41)
Cervical cancer (7)
Clinical research (4265)
Collaboration (189)
Company closure (1)
Compensation (6)
Complete response letters (9)
COVID-19 (228)
C-suite (112)
Cystic fibrosis (8)
Data (312)
Depression (6)
Diabetes (36)
Diagnostics (307)
Digital health (2)
Diversity, equity & inclusion (1)
Drug discovery (18)
Drug pricing (30)
Drug shortages (4)
Duchenne muscular dystrophy (28)
Earnings (2561)
Editorial (8)
Employer branding (5)
Employer resources (8)
Events (2838)
Executive appointments (87)
FDA (1049)
Funding (104)
Gene editing (3)
Generative AI (5)
Gene therapy (48)
GLP-1 (141)
Government (254)
Guidances (11)
Healthcare (617)
Hematology (12)
HIV (5)
Huntington's disease (13)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (3)
Immunology and inflammation (44)
Immuno-oncology (6)
Indications (6)
Infectious disease (243)
Inflammatory bowel disease (19)
Inflation Reduction Act (2)
Influenza (11)
Intellectual property (5)
Interviews (10)
IPO (449)
IRA (11)
Job creations (261)
Job search strategy (70)
JPM (11)
Labor market (7)
Layoffs (66)
Leadership (4)
Legal (286)
Liver cancer (15)
Longevity (2)
Lung cancer (85)
Lymphoma (56)
Machine learning (3)
Management (2)
Manufacturing (75)
MASH (25)
Medical device (190)
Medtech (193)
Mergers & acquisitions (911)
Metabolic disorders (170)
mRNA (17)
Multiple sclerosis (33)
NASH (6)
Neurodegenerative disease (41)
Neuropsychiatric disorders (13)
Neuroscience (241)
Neurotech (1)
NextGen: Class of 2026 (240)
Non-profit (178)
Now hiring (6)
Obesity (119)
Opinion (31)
Ovarian cancer (7)
Pain (3)
Pancreatic cancer (11)
Parkinson's disease (19)
Partnered (1)
Patents (14)
Patient recruitment (13)
Peanut (3)
People (4300)
Pharmacy benefit managers (4)
Phase 1 (1217)
Phase 2 (1701)
Phase 3 (1773)
Pipeline (388)
Policy (34)
Postmarket research (303)
Preclinical (383)
Press Release (1)
Prostate cancer (5)
Psychedelics (4)
Radiopharmaceuticals (12)
Rare diseases (54)
Real estate (217)
Recruiting (5)
Regulatory (1129)
Reports (7)
Research institute (117)
Resumes & cover letters (12)
Rett syndrome (1)
RNA editing (2)
RSV (5)
Schizophrenia (16)
Series A (26)
Series B (20)
Sickle cell disease (2)
Special edition (7)
Spinal muscular atrophy (60)
Sponsored (1)
Startups (220)
Stomach cancer (5)
Supply chain (9)
Tariffs (26)
The Weekly (26)
Vaccines (54)
Venture capital (17)
Weight loss (83)
Women's health (4)
Date
Today (2)
Last 7 days (17)
Last 30 days (106)
Last 365 days (1125)
2026 (582)
2025 (1147)
2024 (1498)
2023 (1509)
2022 (3088)
2021 (2746)
2020 (2389)
2019 (1744)
2018 (1421)
2017 (1444)
2016 (1329)
2015 (1635)
2014 (1182)
2013 (1029)
2012 (1158)
2011 (1243)
2010 (1175)
Location
Africa (67)
Alabama (3)
Arizona (16)
Asia (1451)
Australia (225)
California (468)
Canada (73)
China (74)
Colorado (3)
Connecticut (41)
Delaware (2)
Europe (6787)
Florida (14)
Georgia (12)
Illinois (46)
India (4)
Indiana (29)
Japan (20)
Kansas (1)
Kentucky (2)
Louisiana (1)
Maryland (15)
Massachusetts (331)
Michigan (12)
Minnesota (34)
Missouri (9)
Nevada (3)
New Hampshire (1)
New Jersey (69)
New York (145)
North Carolina (31)
Northern California (285)
Ohio (3)
Oklahoma (1)
Oregon (1)
Pennsylvania (33)
Rhode Island (2)
South America (63)
Southern California (130)
Tennessee (1)
Texas (31)
United States (1406)
Utah (14)
Vermont (1)
Virginia (7)
Washington D.C. (4)
Washington State (88)
Wisconsin (2)
30,613 Results for "roche boehringer mannheim".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments:
Reuters
Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.
June 15, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
Lilly and Boehringer roll back billions in German investments over health budget cuts
With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.
June 4, 2026
·
2 min read
·
Nick Paul Taylor
Inflammatory bowel disease
Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms
Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.
June 23, 2026
·
2 min read
·
Tristan Manalac
Obesity
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction
While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
June 8, 2026
·
2 min read
·
Tristan Manalac
Deals
Roche makes up to $2.3B blood cancer play with Nurix’s protein degrader
Roche and Nurix Therapeutics will advance their BTK degrader for chronic lymphocytic leukemia, as well as immunology and neurology indications.
June 8, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
May 21, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
·
2 min read
·
Heather McKenzie
Breast cancer
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset giredestrant was unsuccessful.
March 9, 2026
·
2 min read
·
Annalee Armstrong
Obesity
ADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonist
Analysts and investors were unimpressed by Phase 2 data posted in the spring showing that an amylin analog developed by Roche and partner Zealand Pharma elicited 9% weight loss, less than Eli Lilly’s rival candidate. Executives from both companies told
BioSpace
that premium weight loss is not the point of petrelintide.
June 5, 2026
·
4 min read
·
Annalee Armstrong
Spinal muscular atrophy
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk facility last year but is now nearing a potential resolution.
March 20, 2026
·
2 min read
·
Tristan Manalac
1 of 3,062
Next
